A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia

NCT03356639 | Completed Phase 1 FDA Drug

• 1 other identifier: 6981-CL-0004
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 2

Brief Summary

The primary purpose is to evaluate the safety and tolerability of ASP6981 in participants with schizophrenia. Also primary purpose is to evaluate the pharmacodynamics of ASP6981 in participants with schizophrenia as measured by cognitive function and neurophysiological biomarkers. The secondary purpose of this study is to evaluate the pharmacokinetics of ASP6981 in participants with schizophrenia.

Conditions

Schizophrenia

Keywords

Schizophrenia; ASP6981; Safety; Phase 1

Outcome Measures

Primary Outcomes (14)

• Safety and tolerability assessed by nature, frequency and severity of adverse events (AEs)

  An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product.

  Up to End of Study (up to a maximum of 65 days)

• Number of participants with vital signs abnormalities and/or adverse events related to treatment

  Number of participants with potentially clinically significant vital sign values.

  Up to End of Study (up to a maximum of 65 days)

• Number of participants with laboratory value abnormalities and/or adverse events related to treatment

  Number of participants with potentially clinically significant laboratory values.

  Up to End of Study (up to a maximum of 65 days)

• Safety and tolerability assessed by 12-lead electrocardiogram (ECG)

  Routine 12 lead ECGs will be performed after the participant has been in a supine position for at least 5 minutes. Any clinically significant adverse changes on the ECG will be reported as (serious) Adverse Event.

  Up to End of Study (up to a maximum of 65 days)

• Safety and tolerability assessed by C-SSRS

  C-SSRS: Columbia - Suicide Severity Rating Scale. The C SSRS is a rating scale that assesses the full spectrum of suicidality: suicide ideation, intensity of ideation, suicidal behaviors and actual attempts.

  Up to 50 days

• Safety and tolerability assessed through metabolic parameter: waist circumference

  Waist circumference will be summarized by ASP6981 treatment group and pooled placebo.

  Up to End of Study (up to a maximum of 65 days)

• Safety and tolerability assessed through metabolic parameter: lipid panel

  Lipid panel will be summarized by ASP6981 treatment group and pooled placebo.

  Up to End of Study (up to a maximum of 65 days)

• Safety and tolerability assessed through metabolic parameter: glucose level

  Glucose level will be summarized by ASP6981 treatment group and pooled placebo.

  Up to End of Study (up to a maximum of 65 days)

• Safety and tolerability assessed by weight

  Weight to be summarized by ASP6981 treatment group and pooled placebo.

  Up to End of Study (up to a maximum of 65 days)

• Safety and tolerability assessed for movement disorder using AIMS

  AIMS: Abnormal Involuntary Movement Scale. The AIMS aids in the early detection of tardive dyskinesia as well as providing a method for on going surveillance. The AIMS is a checklist and uses a 5 point rating scale for recording scores for 7 body areas: face, lips, jaw, tongue, upper extremities, lower extremities and trunk.

  Up to 50 days

• Safety and tolerability assessed for movement disorder using BARS

  BARS: Barnes Akathisia Rating Scale. The BARS is a rating scale that is used to assess the severity of drug induced akathisia.

  Up to 50 days

• Safety and tolerability assessed for movement disorder using SAS

  SAS: Simpson Angus Scale. The SAS is a 10 item scale used to rate adverse neurological effects of antipsychotic medications more broadly. It involves direct observation and a brief neurological examination. Rating requires the investigator to observe the participant's gait and check for tremor, excessive salivation and rigidity in the arms, shoulder and neck. Each item is rated from 0 to 4 and a total score can be obtained.

  Up to 50 days

• Pharmacodynamics (PD) of ASP6981 assessed through Cogstate: general composite score of executive function and memory cognitive testing

  Cogstate testing composed by Groton Maze Learning, One Back, One Card and International Shopping List tests: specific Cogstate's panels for schizophrenia.

  Day 14: period 1 and 2

• PD of ASP6981 assessed through electroencephalogram (EEG): electrophysiological measures of P300 (P3a, P3b) and Mismatch Negativity (MMN)

  EEG will be recorded after cognitive testing.

  Day 14: period 1 and 2

Secondary Outcomes (7)

• Pharmacokinetics (PK) of ASP6981 and its metabolites, if necessary (plasma): Tmax

  Day 1 and day 14: period 1 and 2

• PK of ASP6981 and its metabolites, if necessary (plasma): Cmax

  Day 1 and day 14: period 1 and 2

• PK of ASP6981 and its metabolites, if necessary (plasma): AUC12

  Day 1: period 1 and 2

• PK of ASP6981 and its metabolites, if necessary (plasma): Ctrough

  Day 7 and day 14: period 1 and 2 and day 13 of period 2

• PK of ASP6981 and its metabolites, if necessary (plasma): AUCtau

  Day 14: period 1 and 2

Study Arms (4)

ASP6981 50 mg, then matching Placebo

EXPERIMENTAL

Participants in Sequence AB will first receive ASP6981 capsules orally (50 mg) during period 1. After a 14-day washout period, participants receive matching placebo during period 2. Participants will receive ASP6981 capsules or matching placebo capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, ASP6981 or matching placebo will be administered under fasting conditions.

Drug: ASP6981; Drug: Placebo

Matching Placebo, then ASP6981 50 mg

EXPERIMENTAL

Participants in Sequence BA will first receive matching placebo capsules orally during period 1. After a 14-day washout period, participants receive ASP6981 capsules (50 mg) during period 2. Participants will receive matching placebo or ASP6981 capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, matching placebo or ASP6981 will be administered under fasting conditions.

Drug: ASP6981; Drug: Placebo

ASP6981 135 mg, then matching Placebo

EXPERIMENTAL

Participants in Sequence CD will first receive ASP6981 capsules orally (135 mg) during period 1. After a 14-day washout period, participants receive matching placebo during period 2. Participants will receive ASP6981 capsules or matching placebo every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, ASP6981 or matching placebo will be administered under fasting conditions.

Drug: ASP6981; Drug: Placebo

Matching Placebo, then ASP6981 135 mg

EXPERIMENTAL

Participants in Sequence DC will first receive matching placebo capsules orally during period 1. After a-14 day washout period, participants receive ASP6981 (135 mg) during period 2. Participants will receive matching placebo or ASP6981 capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, matching placebo or ASP6981 will be administered under fasting conditions.

Drug: ASP6981; Drug: Placebo

Interventions

ASP6981 DRUG

Oral

ASP6981 135 mg, then matching Placebo; ASP6981 50 mg, then matching Placebo; Matching Placebo, then ASP6981 135 mg; Matching Placebo, then ASP6981 50 mg

Placebo DRUG

Oral

ASP6981 135 mg, then matching Placebo; ASP6981 50 mg, then matching Placebo; Matching Placebo, then ASP6981 135 mg; Matching Placebo, then ASP6981 50 mg

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Subject has a diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition criteria.
• Subject is considered operationally stable if the subject has a low to moderate positive symptom score and moderate negative symptom score on the PANSS (Positive and Negative Syndrome Scale): no more than moderate rating on more than 2 PANSS items P1, P2, P3, P5, P6; no more than moderate severity rating for the negative items, N1, N2, N3, N4, N5, N6, N7; total PANSS score no more than 80.
• Subject must be in ongoing maintenance antipsychotic therapy (i.e., second generation antipsychotics other than clozapine oral or depot), on a stable (less than or equal to 25% change in dose) medication treatment regimen (approved oral or depot formulations of risperidone, quetiapine, olanzapine, ziprasidone, brexpiprazole, aripiprazole, paliperidone or lurasidone; up to 2 permitted on condition that the second medication is not required to control treatment resistance or intractable psychotic symptoms) for more than or equal to 2 months for oral formulations or more than or equal to 3 months for depot formulations prior to screening, including concomitant psychotropic medications, such as, trazodone and zolpidem for sleep.
• Subject has a body mass index (BMI) range of 18.5 to 40.0 kg/m2, inclusive, and weighs at least 50 kg.
• Subject has a negative urine drug screen for drugs of abuse.
• Female subject must not donate ova starting at screening and throughout the study period, and for 28 days after the final study drug administration.
• Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 28 days after the final study drug administration.
• A sexually active male subject with female partner(s) who are of childbearing potential is eligible if:
• The male subject agrees to use a male condom starting at screening and continue throughout the study period and for 90 days after the final study drug administration.
• The male subject has not had a vasectomy or is not sterile, as defined above, their female partner(s) is utilizing 1 form of highly effective birth control starting at screening and continuing throughout study treatment and for 90 days after the male subject receives their final study drug administration.
• Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 90 days after the final study drug administration.
• Male subject must not donate sperm starting at screening and throughout the study period and for 90 days after the final study drug administration.
• Subject agrees not to participate in another interventional study while participating in the present study, defined as signing the informed consent form until completion of the ESV.

You may not qualify if:

• Female subject who has been pregnant within 6 months prior to screening assessment or breastfeeding within 3 months prior to screening.
• Subject has a known or suspected hypersensitivity to ASP6981 or any components of the formulation used.
• Subject has had previous exposure with ASP6981.
• Subject has a history of heavy smoking (use more than 40 cigarettes/2 packs per day) or a user of nicotine replacement therapy (includes nicotine patches, Chantix or similar therapeutic agents) in the past 3 months prior to admission to the clinical unit (day -3).
• Subject has a history of suicide attempt or suicidal behavior within 2 years prior to screening. Any suicidal ideation that meets criteria at a level of 4 or 5 by using C-SSRS within the last 3 months or who is at significant risk to commit suicide will be excluded.
• Subject has any clinically significant liver chemistry test result (aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], alkaline phosphatase \[ALP\], gamma glutamyl transferase, total bilirubin \[TBL\]) or a result greater than 1.5 x greater than upper limit of normal (ULN). In such a case, the assessment may be repeated once.
• Subject has any history of allergic conditions deemed clinically significant.
• Subject has any history or evidence of any clinically significant cardiovascular, gastro-intestinal endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric (other than schizophrenia or schizoaffective disorder), renal and/or other major disease or malignancy.
• Subject has a history of being diagnosed with moderate or severe tardive dyskinesia, bipolar disorder, major depressive disorder, personality disorders, neuroleptic malignancy syndrome or anxiety disorder.
• Subject has any clinically significant abnormality of the physical examination, ECG and protocol-defined clinical laboratory tests.
• Subject has a mean pulse lower than 40 or greater than 100 bpm; resting systolic blood pressure (SBP) lower than 90 or greater than 180 mmHg, or a resting diastolic blood pressure (DBP) greater than 100 mmHg at screening and on day -3 (measurements taken in triplicate after subject has been resting in supine position for 5 minutes; pulse will be measured automatically). If the mean blood pressure exceeds the limits above, 1 additional triplicate can be taken at screening and on day -3.
• Subject has a mean QT interval using Fridericia's correction (QTcF) of greater than 450 ms (for male subjects) and greater than 470 ms (for female subjects). If the mean QTcF exceeds the limits above, 1 additional triplicate ECG can be taken at screening and on day -3.
• Subject uses any prescribed (including current treatment with anticholinergic medications such as benztropine, biperiden, procyclidine, and trihexyphenidyl) or nonprescribed drugs (including vitamins, natural and herbal remedies, e.g., valerian) in the 2 weeks prior to study drug administration until the ESV, except for:
• Approved second generation antipsychotics (risperidone, quetiapine, olanzapine, ziprasidone, brexpiprazole, aripiprazole, paliperidone or lurasidone), or
• Approved intermittent use of short-acting hypnotic agents trazodone or zolpidem (no less than 12 hours prior to dosing), or

Sponsors & Collaborators

• Astellas Pharma Global Development, Inc.: lead

Study Sites (2)

Cctmg/Parexel

Glendale, California, 91206, United States

Location

Community Clinical Research

Austin, Texas, 78754, United States

Location

Related Links

• Link to results on Astellas Clinical Study Results website

MeSH Terms

Conditions

Schizophrenia

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders

Study Officials

• Senior Medical Director

  Astellas Pharma Global Development, Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 28, 2017
• First Posted: November 29, 2017
• Study Start: January 22, 2018
• Primary Completion: May 30, 2018
• Study Completion: May 30, 2018
• Last Updated: October 31, 2024

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will not share

Locations

US (2)